372 related articles for article (PubMed ID: 32362221)
1. Amoxicillin or tetracycline in bismuth-containing quadruple therapy as first-line treatment for
Bang CS; Lim H; Jeong HM; Shin WG; Choi JH; Soh JS; Kang HS; Yang YJ; Hong JT; Shin SP; Suk KT; Lee JJ; Baik GH; Kim DJ
Gut Microbes; 2020 Sep; 11(5):1314-1323. PubMed ID: 32362221
[TBL] [Abstract][Full Text] [Related]
2. Comparison of Helicobacter pylori eradication rates between 7 and 14 days of tailored therapy according to clarithromycin resistance test: A randomized, multicenter, non-inferiority study.
Jung K; Jee SR; Lee MW; Koh M; Kim SJ; Lee J; Park MI
Helicobacter; 2024; 29(3):e13084. PubMed ID: 38717034
[TBL] [Abstract][Full Text] [Related]
3. Efficacy comparison of 7- and 14-day P-CAB based bismuth-containing quadruple regimen with PPI based bismuth-containing quadruple regimen for Helicobacter pylori infection: rationale and design of an open-label, multicenter, randomized controlled trial.
Oh CK; Lim H; Seo SI; Lee SP; Bang CS; Shin WG; Kim JB; Jang HJ; Baik GH
BMC Gastroenterol; 2023 Dec; 23(1):453. PubMed ID: 38129806
[TBL] [Abstract][Full Text] [Related]
4. Role of proton pump inhibitors dosage and duration in Helicobacter pylori eradication treatment: Results from the European Registry on H. pylori management.
Pabón-Carrasco M; Keco-Huerga A; Castro-Fernández M; Saracino IM; Fiorini G; Vaira D; Pérez-Aísa Á; Tepes B; Jonaitis L; Voynovan I; Lucendo AJ; Lanas Á; Martínez-Domínguez SJ; Almajano EA; Rodrigo L; Vologzanina L; Brglez Jurecic N; Denkovski M; Bujanda L; Abdulkhakov RA; Huguet JM; Fernández-Salazar L; Alcaide N; Velayos B; Silkanovna Sarsenbaeva A; Zaytsev O; Ilchishina T; Barrio J; Bakulin I; Perona M; Alekseenko S; Romano M; Gravina AG; Núñez Ó; Gómez Rodríguez BJ; Ledro-Cano D; Pellicano R; Bogomolov P; Domínguez-Cajal M; Almela P; Gomez-Camarero J; Bordin DS; Gasbarrini A; Kupčinskas J; Cano-Català A; Moreira L; Nyssen OP; Mégraud F; O'Morain C; Gisbert JP;
United European Gastroenterol J; 2024 Feb; 12(1):122-138. PubMed ID: 38050339
[TBL] [Abstract][Full Text] [Related]
5. Fourteen-day vonoprazan-based bismuth quadruple therapy for H. pylori eradication in an area with high clarithromycin and levofloxacin resistance: a prospective randomized study (VQ-HP trial).
Tungtrongchitr N; Bongkotvirawan P; Ratana-Amornpin S; Siramolpiwat S; Eiamsitrakoon T; Gamnarai P; Wongcha-Um A; Yamaoka Y; Pawa KK; Vilaichone RK
Sci Rep; 2024 Apr; 14(1):8986. PubMed ID: 38637591
[TBL] [Abstract][Full Text] [Related]
6. Two Different 1-Week Quadruple Therapies Given Back-to-Back Consecutive Therapy for Difficult-to-Treat Helicobacter pylori Infection: A Pilot Study.
Liu J; Ji CR; Li YY; Qiao C; Hu JN; Wan M; Lin MJ; Lin BS; Wang J; Zha J; Li LX; Zuo XL
Clin Transl Gastroenterol; 2021 Aug; 12(8):e00391. PubMed ID: 34397042
[TBL] [Abstract][Full Text] [Related]
7. Efficacy and safety of triple therapy containing berberine, amoxicillin, and vonoprazan for Helicobacter pylori initial treatment: A randomized controlled trial.
Chen S; Shen W; Liu Y; Dong Q; Shi Y
Chin Med J (Engl); 2023 Jul; 136(14):1690-1698. PubMed ID: 37469024
[TBL] [Abstract][Full Text] [Related]
8. 14-day tailored PCR-guided triple therapy versus 14-day non-Bismuth concomitant quadruple therapy for Helicobacter pylori eradication: A multicenter, open-label randomized noninferiority controlled trial.
Amiot A; Hacoon J; Heluwaert F; Mion F; Lamarque D; Moussata D; Mimouni M; Delchier JC; Durand-Zaleski I; Audureau E; Bastuji-Garin S;
Helicobacter; 2024; 29(2):e13076. PubMed ID: 38680067
[TBL] [Abstract][Full Text] [Related]
9. Long-term follow up Helicobacter Pylori reinfection rate after second-line treatment: bismuth-containing quadruple therapy versus moxifloxacin-based triple therapy.
Kim MS; Kim N; Kim SE; Jo HJ; Shin CM; Park YS; Lee DH
BMC Gastroenterol; 2013 Sep; 13():138. PubMed ID: 24050512
[TBL] [Abstract][Full Text] [Related]
10. Furazolidone, amoxicillin, bismuth and rabeprazole quadruple rescue therapy for the eradication of Helicobacter pylori.
Cheng H; Hu FL
World J Gastroenterol; 2009 Feb; 15(7):860-4. PubMed ID: 19230048
[TBL] [Abstract][Full Text] [Related]
11. Ten-day bismuth-containing quadruple therapy versus 7-day proton pump inhibitor-clarithromycin containing triple therapy as first-line empirical therapy for the Helicobacter pylori infection in Korea: a randomized open-label trial.
Kim YI; Lee JY; Kim CG; Park B; Park JY; Choi IJ
BMC Gastroenterol; 2021 Mar; 21(1):95. PubMed ID: 33653284
[TBL] [Abstract][Full Text] [Related]
12. Efficacy of two-week therapy with doxycycline-based quadruple regimen versus levofloxacin concomitant regimen for helicobacter pylori infection: a prospective single-center randomized controlled trial.
Alhalabi M; Alassi MW; Alaa Eddin K; Cheha K
BMC Infect Dis; 2021 Jul; 21(1):642. PubMed ID: 34218802
[TBL] [Abstract][Full Text] [Related]
13. Berberine containing quadruple therapy for initial Helicobacter pylori eradication: An open-label randomized phase IV trial.
Zhang D; Ke L; Ni Z; Chen Y; Zhang LH; Zhu SH; Li CJ; Shang L; Liang J; Shi YQ
Medicine (Baltimore); 2017 Aug; 96(32):e7697. PubMed ID: 28796053
[TBL] [Abstract][Full Text] [Related]
14. Comparison of three different regimens against Helicobacter pylori as a first-line treatment: A randomized clinical trial.
Kefeli A; Basyigit S; Yeniova AO; Kefeli TT; Aslan M; Tanas O
Bosn J Basic Med Sci; 2016 Jan; 16(1):52-7. PubMed ID: 26773183
[TBL] [Abstract][Full Text] [Related]
15. Rifabutin-Containing Triple Therapy Versus Bismuth Quadruple Therapy for Helicobacter pylori Rescue Treatment: A Multicenter, Randomized Controlled Trial.
Chen J; Guo Y; Huang Y; Ding Z; Wang J; Liang X; Xu P; Han Y; Lu H
J Infect Dis; 2023 Aug; 228(5):511-518. PubMed ID: 37079894
[TBL] [Abstract][Full Text] [Related]
16. Real-world practice of Helicobacter pylori management: A survey among physicians in Southeast Asia.
Quach DT; Vilaichone RK; Luu MN; Lee YY; Ang TL; Miftahussurur M; Aye TT; Basir DN; Vutha K; Vannarath S; Sollano JD; Mahachai V
Helicobacter; 2023 Dec; 28(6):e13018. PubMed ID: 37634226
[TBL] [Abstract][Full Text] [Related]
17. Current Trends in the Management of Helicobacter pylori Infection in Serbia: Preliminary Results from the European Registry on H. pylori Management.
Milivojevic V; Babic I; Kekic D; Rankovic I; Sagdati S; Panic N; Spasic IS; Krstic M; Milosavljevic T; Moreira L; Nyssen OP; Mégraud F; O' Morain C; Gisbert J
Dig Dis; 2023; 41(3):377-386. PubMed ID: 37253341
[TBL] [Abstract][Full Text] [Related]
18. Efficacy of quadruple therapy with clarithromycin based on faecal molecular antimicrobial susceptibility tests as first-line treatment for
Wu Y; Wang Y; Liu X; Liao O; Lou G; Li Y; Wu H; Du Q; Ye J
BMJ Open; 2023 Jul; 13(7):e072670. PubMed ID: 37479526
[TBL] [Abstract][Full Text] [Related]
19. Comparison of vonoprazan-based with rabeprazole-based dual therapy for treatment-naive patients of Helicobacter pylori infection: a prospective, multi-center, randomized controlled study.
Han YY; Zhou L; Hu YL; Ding XW; Long H; Liu F; Xu M; Zhang ZY; Li SL; Wang QY; Su CX; Chen Y; Chen J; Lin Y; Li PY
J Gastroenterol; 2023 Dec; 58(12):1167-1177. PubMed ID: 37777987
[TBL] [Abstract][Full Text] [Related]
20. Susceptibility-guided sequential strategy versus empirical therapy for Helicobacter pylori infection: study protocol for a randomised controlled trial.
Lu K; Lang C; Zou X; Zang L; Sang W; Feng Q; Mu Y; Liu L; Xu C; Zhao J
Trials; 2023 Jun; 24(1):413. PubMed ID: 37337241
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]